Approach

Summary

Licensing status

Publication and contact information

Markersw

Creatine riboside and N-acetylneuraminic acid (NANA) levels in urine as biomarkers of non-small cell lung cancer (NSCLC)

Patient studies suggest creatine riboside and NANA levels in urine could help diagnose or predict prognosis in NSCLC. In urine samples from 469 patients with NSCLC and 536 healthy individuals, creatine riboside and NANA were elevated in patient samples, with higher levels associated with worse prognosis. Results were validated in urisne samples from an additional cohort of 158 recently diagnosed patients with NSCLC. Next steps include validating the biomarkers in prospective studies in additional patients with lung cancer.

SciBX 7(20); doi:10.1038/scibx.2014.601
Published online May 22, 2014

Patent application filed; available for licensing

Mathe, E.A. et al. Cancer Res.; published online April 15, 2014;
doi:10.1158/0008-5472.CAN-14-0109
Contact: Curtis C. Harris, National Institutes of Health, Bethesda, Md.
e-mail:

curtis_harris@nih.gov